Strata Critical Medical, Inc. Cash Flow Statement
SRTA|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
Strata Critical Medical, Inc. used $3M in operating cash flow and negative free cash flow of $33M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | -$27.3M | -$56.1M | -$27.3M | -$40.1M | -$10.8M |
| Depreciation & Amortization | $6.0M | $7.1M | $5.7M | $596.0K | $472.0K |
| Operating Cash Flow | -$2.5M | -$32.3M | -$37.1M | -$15.6M | -$10.3M |
| Capital Expenditures | $30.9M | $2.1M | $730.0K | $297.0K | $604.0K |
| Free Cash Flow | -$33.4M | -$34.5M | -$37.9M | -$15.9M | -$10.9M |
| Share Buybacks | $244.0K | $0 | - | - | - |
| FCF Margin | -22.7% | -15.3% | -25.9% | -31.5% | -35.0% |